Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Biotech Growth Trust approves buyback of up to 14.99% of shares

Shareholders of Biotech Growth Trust voted in favour of a special resolution to buy back up to 14.99% of the issued share capital, with 99.7% approval. At the time of the annual general meeting, 21,956,234 ordinary shares were issued. The measure is part of the capital management strategy, details of which were set out on 15 October 2025; the formal voting result and the text of the resolution will be published and filed at Companies House. » Altro su de.investing.com
Biotech Growth Trust applies to extend share buyback programme

Biotech Growth Trust will renew the authority to repurchase its own shares and asks shareholders to approve this at the annual general meeting on 12 November 2025. To date the investment trust has repurchased 2,710,338 shares (10.7% of the capital) and expects the current capacity to be exhausted within weeks or months. The board is proposing authority to buy up to 14.99% of the issued shares, valid until the annual general meeting in 2026. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 1999, BIOTECH GROWTH TR. LS-,25 ha già distribuito 0,015 € di dividendi. L'ultimo pagamento è avvenuto a agosto 1999.

Dati finanziari dell'azienda

Nell'ultimo trimestre, BIOTECH GROWTH TR. LS-,25 ha registrato ricavi pari a 73,01 Mln € e un utile netto di 69,6 Mln €

(EUR)	mar 2026	YoY
Ricavi	73,01 Mln	-
Utile lordo	71,5 Mln	-
Utile netto	69,6 Mln	-
EBITDA	70,54 Mln	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	387,98 Mln €
Numero di azioni	19,11 Mln
Massimo/minimo a 52 settimane	20,87 € - 10,30 €
Dividendi	No
Beta	0,59
Rapporto P/E	3,11
Rapporto PEG	0,00
Rapporto P/B	1,31
Rapporto P/S	2,46

Profilo aziendale

Der Biotech Growth Trust PLC ist ein geschlossener Aktienfonds, der von Frostrow Capital LLP aufgelegt wurde. Er wird von OrbiMed Capital LLC mitverwaltet. Der Fonds investiert in öffentliche Aktienmärkte auf der ganzen Welt. Er versucht, in Aktien von Unternehmen zu investieren, die im Biotechnologiesektor tätig sind. Der Fonds investiert in Aktien von Unternehmen jeglicher Marktkapitalisierung. Er setzt bei der Zusammenstellung seines Portfolios die Fundamentalanalyse ein. Der Fonds vergleicht die Wertentwicklung seines Portfolios mit dem NASDAQ Biotechnology Index. Er war zuvor unter dem Namen Finsbury Emerging Biotechnology Trust PLC bekannt. Der Biotech Growth Trust PLC wurde am 20. Mai 1997 gegründet und hat seinen Sitz im Vereinigten Königreich.